The technology transfer from fundamental research to the pharmaceutical industry is a fast evolving process. Big corporations tend more and more to outsource their R&D while investors aim to keep track of new discoveries early on in the research phase.
In this context, Debiopharm Group, through Debiopharm and Debioinnovation, opted for a business model focused on the in-licensing, development, and out-licensing of molecules and biologics. This partnership-based approach allows biotech companies or research institutes to accelerate the development of promising molecules while mitigating their risks and maximizing the opportunity to register a drug.
swissnex San Francisco welcomes Debiopharm executives and professionals from research and the pharmaceutical industry for an interactive discussion around the Swiss-based biopharmaceutical group’s unique business model and new tactics in drug development between universities, biotech companies, and investors.
Thierry Mauvernay, Delegate of the Board, Debiopharm Group
Thierry Mauvernay received his Master of Science in Economics in 1975. He then obtained an MBA from the ‘Institut d’Administration des Entreprises’ and a ‘Diplôme d’Études Supérieures Spécialisées en Marketing’ (MA) in Clermont Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he later sold but continued to manage until July 2001, when he joined Debiopharm SA as Executive Vice President with direct responsibilities over the Finance and Administration Department. In 2006, he handed over his operational activities within Debiopharm SA and has since focused on the administration, finance, and strategy of the Debiopharm Group.
Bertrand Ducrey, Chief Executive Officer, Debiopharm
Dr. Bertrand Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switerland, in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debio R.P. in 1995 as Pharmaceutical Project Manager. He then spent two years at Debiopharm S.A. as Innovative Formulation Manager. In 2004, he returned to Debio R.P. to head the company as Chief Executive Officer. Since 2012, he has led Debiopharm SA as CEO.
Dr. Andrés McAllister, Chief Scientific Officer, Debiopharm
Dr. Andrés McAllister graduated from Medical School in 1985 in Bogota, Colombia, and in 1991, obtained a Ph.D. in Molecular Virology from the Pasteur Institute in Paris, France. Previous job experience includes the Pasteur Institute in Paris; the University of California at San Francisco; the Centre d’Immunologie Pierre Fabre in France; and Director of R&D at Immune Design Molecules, a biotechnology company specialized in the immunotherapy of cancer. He joined Debiopharm SA in 2004.
Dr. David Deperthes, Director, Business Development & Licensing, Debiopharm
Dr. David Deperthes received his Biochemistry Diploma from the University of Laval (Québec), Canada, and obtained his Ph.D. in molecular biology in 1996. He has worked as ‘Research Unit Head’ of the urology unit of the Lausanne University hospital (CHUV) for five years. He founded and managed the Swiss Biotech Company Med Discovery SA, Geneva, and its spin-out Dermadis, specialized in Dermatology. He has acquired strong experience in technology valorization encompassing patent application, IP strategy, and in-/out-licensing from/to worldwide universities and large pharmaceutical companies. Deperthes is also an expert for WIPO (World Intellectual Property Organization) and acts as jury for several entrepreneurship foundations. He joined Debiopharm SA in 2012.
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs and therapies that target unmet medical needs. Oncology is the group’s main area of expertise. In addition, Debiopharm develops or co-develops drugs for specific indications in the following therapeutic areas: infectious diseases, metabolic diseases, immune-mediated diseases and neurodegenerative disorders.
Debiopharm is fully committed to developing the molecules that it licences-in while bearing the entire financial risk of the development process. Debioinnovation works to add synergies to the core drug development expertise and business focus of Debiopharm Group through the financing of biotech start-up companies.
Photo: Myleen Hollero